Kymera Therapeutics stock hits 52-week high at 53.31 USD

Kymera Therapeutics Inc stock has reached a new 52-week high, touching 53.31 USD. This milestone reflects a positive trajectory for the company, with an impressive 65% surge over the past six months and a 30.5% gain year-to-date. According to InvestingPro analysis, the stock is currently trading slightly above its Fair Value, with 11 analysts recently revising their earnings expectations upward. Over the last 12 months, Kymera Therapeutics has experienced significant price movements, with a beta of 2.18 indicating higher volatility than the broader market. This upward movement comes amid ongoing developments and investor interest in the company’s innovative therapeutic solutions. The achievement of this 52-week high underscores the market’s confidence in Kymera’s potential and its strategic initiatives moving forward. Discover more insights and 12 additional ProTips about Kymera with an InvestingPro subscription.

In other recent news, Kymera Therapeutics reported its Q2 2025 earnings, which revealed a larger-than-expected loss. The company posted an earnings per share of -$0.95, missing the forecast of -$0.83, and revenue for the quarter was $11.5 million, falling short of the $20 million forecast. In response to these results, several analysts have adjusted their outlooks on the company. Wolfe Research raised its price target for Kymera Therapeutics to $88, citing the potential of its KT-621 drug. H.C. Wainwright also increased its price target to $70 while maintaining a Buy rating, following the presentation of comprehensive data for KT-621. Barclays initiated coverage on Kymera with an Overweight rating and a $60 price target, highlighting encouraging early clinical data. Additionally, RBC Capital began coverage with an Outperform rating and a $70 price target, expressing confidence in the drug’s potential in upcoming Phase Ib readouts. These developments reflect ongoing interest and analysis of Kymera’s potential in the pharmaceutical market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.